3 Reasons TAVR Will Continue to Prosper

The transcatheter aortic valve replacement (TAVR) market has already seen rapid growth, and today represents a $3 billion market globally. But the leading TAVR companies say the current technology and approved indications barely scratches the surface in terms of the true growth potential of the space. Michael Mussallem, CEO of Edwards Lifesciences, told J.P. Morgan Healthcare Conference attendees on Monday that the global TAVR market is expected to exceed $5 billion by 2021, and that number does not include certain indications that are currently being explored, like treatment for patients with asymptomatic aortic stenosis (AS) or moderate AS. Several experts from Edwards Lifesciences will speak at the MD&M West Conference, February 6-8, 2018, in Anaheim, CA. Register now using the promo code "MDDI" to get 20% off registration and free access to the expo. Today, the three primary growth drivers in TAVR are indication expansion, technology advances, and improved awareness of the therapy. "We love the progress we've made, but having said that, the practice of medicine changes very slowly," Mussallem said. "There are several groups that are not addressed by what is approved today." Many thought leaders in the past have pointed out that the approval trajectory in the TAVR market seems backward because patients have to be very ill to be eligible for the therapy. So Edwards and its peers in the space have turned their focus over the past couple of years to seeking expanded lab...
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Source Type: news